Replies to post #208699 on Biotech Values

[mcbio]

AMGN/(ESPR) -

Yes, to a degree; however, until we know the HR achieved on the primary MACE endpoint in the Repatha CVOT, I would remain cautious.

Is there any particular range of HR you have in mind for Repatha CVOT that you'd consider bullish for ESPR?